Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

This study tests whether cetuximab (a targeted antibody drug that blocks a growth signal called EGFR) can help people with head and neck cancer whose disease progressed after receiving immunotherapy. It is intended for patients who have already tried immune checkpoint therapy and need another option. **You may be eligible if...** - You are 18 or older - You have confirmed head and neck squamous cell cancer with measurable disease - You have already received immunotherapy (a PD-1 inhibitor), either alone or with chemotherapy - You are in generally good health (performance status 0-2) - You are willing and able to follow the study schedule **You may NOT be eligible if...** - You have previously been treated with cetuximab or any other drug targeting EGFR in the last 5 years - You had an allergic reaction to cetuximab - You have interstitial lung disease (lung scarring or inflammation) - You have had a stroke, heart attack, or blood clot in the past 6-12 months - You have a serious or non-healing wound or bone fracture - You are currently on immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.